• 1
    Fujisawa D, Nakagawa A, Sado M et al. Current Status and Dissemination of Psychotherapies in Japan. Japan Ministry of Health and Labor, Tokyo, 2006.
  • 2
    Fujisawa D, Nakagawa A, Tajima M et al. Cognitive behavioral therapy for depression among adults in Japanese clinical settings: A single-group study. BMC Res. Notes 2010; 7: 160.
  • 3
    Yoshimura S, Ueda K, Suzuki SI et al. Self-referential processing of negative stimuli within the ventral anterior cingulate gyrus and right amygdala. Brain Cogn. 2009; 69: 218225.
  • 4
    Onoda K, Okamoto Y, Nakashima K et al. Decreased ventral anterior cingulate cortex activity is associated with reduced social pain during emotional support. Soc. Neurosci. 2009; 4: 443454.
  • 5
    Yoshimura S, Okamoto Y, Onoda K et al. Rostral anterior cingulate cortex activity mediates the relationship between the depressive symptoms and the medial prefrontal cortex activity. J. Affect. Disord. 2010; 122: 7685.
  • 6
    Okamoto Y. Functional brain basis of pathophysiology in depression. Seishin Shinkeigaku Zasshi 2009; 111: 13301344 (in Japanese).
  • 7
    Matsunaga M, Okamoto Y, Suzuki SI et al. Psychosocial functioning in patients with treatment-resistant depression after group cognitive behavioral therapy. BMC Psychiatry 2010; 10: 22.
  • 8
    Watanabe N, Furukawa TA, Shimodera S et al. Brief behavioral therapy for refractory insomnia in residual depression: Assessor-blind, randomized controlled trial. J. Clin. Psychiatry (in press).
  • 9
    Kobayashi K, Shimizu E, Hashimoto K et al. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 29: 658663.
  • 10
    Sakai Y, Kumano H, Nishikawa M et al. Changes in cerebral glucose utilization in patients with panic disorder treated with cognitive-behavioral therapy. Neuroimage 2006; 33: 218226.
  • 11
    Nakano Y, Lee K, Noda Y et al. Cognitive-behavior therapy for Japanese patients with panic disorder: Acute phase and one-year follow-up results. Psychiatry Clin. Neurosci. 2008; 62: 313321.
  • 12
    Wade WA, Treat TA, Stuart GL. Transporting an empirically supported treatment for panic disorder to a severe clinic setting: A benchmarking strategy. J. Consult. Clin. Psychol. 1998; 66: 231239.
  • 13
    Martinsen EW, Olsen T, Tonset E et al. Cognitive-behavioral group therapy for panic disorder in the general clinical setting: A naturalistic study with 1-year follow-up. J. Clin. Psychiatry 1998; 59: 437442.
  • 14
    Hahlweg K, Fiegenbaum W, Frank M et al. Short- and long-term effectiveness of an empirically supported treatment for agoraphobia. J. Consult. Clin. Psychol. 2001; 69: 375382.
  • 15
    Barlow DH, Gorman JM, Shear MK et al. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 25292536.
  • 16
    Perini SJ, Slade T, Andrews A. Generic effectiveness measures: Sensitivity to symptom change in anxiety disorders. J. Affect. Disord. 2006; 90: 123130.
  • 17
    Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: Systematic review. Br. J. Psychiatry 2006; 188: 305312.
  • 18
    Furukawa T, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database Syst. Rev. 2007; (1): CD004364.
  • 19
    Furukawa TA, Watanabe N, Omori IM. Can pill placebo augment cognitive-behavior therapy for panic disorder? BMC Psychiatry 2007; 7: 73.
  • 20
    Lee K, Noda Y, Nakano Y et al. Interoceptive hypersensitivity and interoceptive exposure in patients with panic disorder: Specificity and effectiveness. BMC Psychiatry 2006; 6: 32.
  • 21
    Noda Y, Nakano Y, Lee K et al. Sensitization of catastrophic cognition in cognitive-behavioral therapy for panic disorder. BMC Psychiatry 2007; 7: 70.
  • 22
    Ogawa S, Furukawa TA, Nakano Y et al. Interoceptive hypersensitivity as prognostic factor among patients with panic disorder who have received cognitive behavioral therapy. J. Behav. Ther. Exp. Psychiatry 2010; 41: 325329.
  • 23
    Watanabe N, Churchill R, Furukawa TA. Combination of psychotherapy and benzodiazepines versus either therapy alone for panic disorder: A systematic review. BMC Psychiatry 2007; 7: 18.
  • 24
    Watanabe N, Churchill R, Furukawa TA. Combined psychotherapy plus benzodiazepines for panic disorder. Cochrane Database Syst. Rev. 2009; (1): CD005335.
  • 25
    Chen J, Nakano Y, Ietzugu T et al. Group cognitive behavior therapy for Japanese patients with social anxiety disorder: Preliminary outcomes and their predictors. BMC Psychiatry 2007; 7: 69.
  • 26
    Furukawa TA, Chen J, Watanabe N et al. Videotaped experiments to drop safety behaviors and self-focused attention for patients with social anxiety disorder: Do they change subjective and objective evaluations of anxiety and performance? J. Behav. Ther. Exp. Psychiatry 2009; 40: 202210.
  • 27
    Chen J, Furukawa TA, Nakano Y et al. Video feedback with peer ratings in naturalistic anxiety-provoking situations for social anxiety disorder: Preliminary report. J. Behav. Ther. Exp. Psychiatry 2010; 41: 610.
  • 28
    Heimberg RG, Liebowitz MR, Hope DA et al. Cognitive behavioral group therapy for social phobia: 12-week outcome. Arch. Gen. Psychiatry 1998; 55: 11331141.
  • 29
    Stangier U, Hedenreich T, Peitz M et al. Cognitive therapy for social phobia: Individual versus group treatment. Behav. Res. Ther. 2003; 41: 9911007.
  • 30
    Mortberg E, Clark DM, Sundin O et al. Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: A randomized controlled trial. Acta Psychiatr. Scand. 2007; 115: 142154.
  • 31
    Nakatani E, Nakagawa A, Nakao T et al. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder: Effectiveness of behavior therapy and fluvoxamine. Psychother. Psychosom. 2005; 74: 269276.
  • 32
    Nakatani E, Nakagawa A. Outcome of additional behaviour therapy including treatment discontinuation for fluvoxamine non-responders with obsessive-compulsive disorder. Psychother. Psychosom. 2008; 77: 393394.
  • 33
    Okajima M, Hashimoto K, Noguchi Y et al. Treatment outcome of obsessive compulsive disorder. Seishinka-Chiryogaku 2007; 22: 509516 (in Japanese).
  • 34
    Yamamoto M, Iikura Y, Miyakawa A. Research of inpatients with obsessive-compulsive symptom regarding reasons for hospitalization, applied treatment methods, and treatment effects. Seishin-Igaku 2006; 48: 391398 (in Japanese).
  • 35
    Yoshida H, Konishi T, Kamo T. Trial of prolonged exposure therapy for chronic post traumatic stress disorder in Japan. Jpn. J. Gen. Hosp. Psychiatry 2008; 20: 5562 (Abstract, in English).
  • 36
    Asukai N, Saito A, Tsuruta N et al. Pilot study on prolonged exposure of Japanese patients with posttraumatic stress disorder due to mixed traumatic events. J. Trauma. Stress 2008; 21: 340343.
  • 37
    Foa EB, Hembree EA, Cahill SP et al. Randomized trial of prolonged exposure for posttraumatic stress disorder with and without cognitive restructuring: Outcome at academic and community clinics. J. Consult. Clin. Psychol. 2005; 73: 953964.
  • 38
    Schnurr PP, Friedman MJ, Engel CC et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized controlled trial. JAMA 2007; 297: 820830.
  • 39
    Ishii T, Ono Y, Takeda R et al. Trial of dialectical behaviour therapy for borderline personality disorder in Japan. Jpn. J. Cogn. Ther. 2009; 2: 4244 (in Japanese).
  • 40
    Ishii T. Dialectical behaviour therapy for borderline personality disorder in Japan. Kokoro rinsho, a rakaruto 2007; 26: 599603 (in Japanese).